A Study to Evaluate the Efficacy and Safety of Adjunctive Troriluzole in Obsessive-Compulsive Disorder

Phase 3 Completed 589 enrolled Biohaven Pharmaceuticals, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study was to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in participants with Obsessive Compulsive Disorder (OCD).

Timeline

Start: 2021-01-29
Primary completion: 2025-04-29
Completion: 2025-04-29

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Troriluzole	Peptide	280 mg	Oral

A Study to Evaluate the Efficacy and Safety of Adjunctive Troriluzole in Obsessive-Compulsive Disorder

Summary

Timeline

Drugs

Indications